Nuvation Bio (Nuvation Bio) EBIT per Share : $0.00 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio EBIT per Share?

Nuvation Bio's EBIT per Share for the three months ended in Dec. 2023 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

During the past 3 years, the average EBIT per Share Growth Rate was -31.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Nuvation Bio's EBIT per Share or its related term are showing as below:

NUVB.WS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -31.6 Med: -31.6 Max: -31.6
Current: -31.6

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Nuvation Bio was -31.60% per year. The lowest was -31.60% per year. And the median was -31.60% per year.

NUVB.WS's 3-Year EBIT Growth Rate is ranked worse than
82.53% of 1305 companies
in the Biotechnology industry
Industry Median: 3.5 vs NUVB.WS: -31.60

Nuvation Bio's EBIT for the three months ended in Dec. 2023 was $-20.83 Mil.

Nuvation Bio EBIT per Share Historical Data

The historical data trend for Nuvation Bio's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio EBIT per Share Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial											-	-	-	-	-

Nuvation Bio EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Nuvation Bio's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-99.822	/	0
=	N/A

Nuvation Bio's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-20.831	/	0
=	N/A

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

Nuvation Bio (NYSE:NUVB.WS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Nuvation Bio EBIT per Share Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

NUVB:USA

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).